Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure

2002 ◽  
Vol 143 (5) ◽  
pp. 910-915 ◽  
Author(s):  
Michael Tauchert
Keyword(s):  
Heart Failure ◽  
New York ◽  
Heart Association ◽  
York Heart Association Class ◽  
Efficacy And Safety ◽  
Class Iii ◽  
Association Class ◽  
New York Heart Association

scholarly journals CardioMEMS Implantation Using Gadolinium-based Contrast Agent: A Case Report

2021 ◽  
Vol 7 ◽  
Author(s):  
Aniket S Rali ◽  
Lynne W Stevenson ◽  
Sandip K Zalawadiya
Keyword(s):  
Heart Failure ◽  
New York ◽  
Contrast Agent ◽  
Heart Association ◽  
York Heart Association Class ◽  
Class Iii ◽  
Device Implantation ◽  
Association Class ◽  
New York Heart Association ◽  
History Of

A 57-year-old woman with New York Heart Association Class III heart failure requiring multiple hospitalisations over the previous year presented for CardioMEMS implantation. Because of the patient’s allergy history of anaphylaxis to iodine-based contrast agent she underwent the device implantation with gadolinium-based contrast agent (Magnevist), which was successful.

Patients with New York Heart Association class III heart failure may benefit with high flow nasal cannula supportive therapy

2013 ◽  
Vol 28 (5) ◽  
pp. 741-746 ◽  
Author(s):  
Oriol Roca ◽  
Purificación Pérez-Terán ◽  
Joan R. Masclans ◽  
Lourdes Pérez ◽  
Enrique Galve ◽  
...  
Keyword(s):  
Heart Failure ◽  
New York ◽  
Supportive Therapy ◽  
Heart Association ◽  
High Flow ◽  
York Heart Association Class ◽  
Class Iii ◽  
High Flow Nasal Cannula ◽  
Association Class ◽  
New York Heart Association

scholarly journals Patients’ Willingness to Accept Mitral Valve Procedure-Associated Risks Varies Across Severity of Heart Failure Symptoms

2019 ◽  
Vol 12 (12) ◽  
Author(s):  
Shelby D. Reed ◽  
Angelyn O. Fairchild ◽  
F. Reed Johnson ◽  
Juan Marcos Gonzalez ◽  
Robert J. Mentz ◽  
...  
Keyword(s):  
Heart Failure ◽  
New York ◽  
Mitral Valve ◽  
Physical Functioning ◽  
Heart Association ◽  
York Heart Association Class ◽  
Class Iii ◽  
Patients With Heart Failure ◽  
Association Class ◽  
New York Heart Association

Background: The Food and Drug Administration’s Center for Devices and Radiological Health issued Guidance in 2016 on generating patient preference information to aid evaluation of medical devices. Consistent with this guidance, we aimed to provide quantitative patient preference evidence on benefit-risk tradeoffs relevant to transcatheter mitral valve repair versus medical therapy for patients with heart failure and symptomatic secondary mitral regurgitation. Methods: A discrete-choice experiment survey was designed to quantify patients’ tolerance for 30-day mortality or serious bleeding risks to achieve improvements in physical functioning or reductions in heart failure hospitalizations. Two samples were recruited: an online US panel of individuals reporting a diagnosis of heart failure (n=244) and patients with heart failure treated at Duke University Health System (n=175). Random-effects logit regression was used to model treatment choices as a function of benefit and risk levels. Results: Across both samples, approximately one-quarter (23.5%) consistently chose device profiles offering the higher level of physical functioning despite mortality and bleeding risks as high as 10%. Among respondents who at least once chose a device profile offering a lower level of functioning, improvement in physical functioning equivalent to a change from New York Heart Association class IV to III was ≈6 times more preferred than a change from New York Heart Association class III to II. Estimated discrete-choice experiment utility gains and losses revealed that respondents would accept up to a 9.7 percentage-point (95% CI, 8.2%–13.3%) increase in risk of 30-day mortality with devices that could improve functioning from New York Heart Association class IV to III, or up to 2.0% (95% CI, 1.4%–2.7%) for an improvement from New York Heart Association class III to II. Conclusions: Severity of heart failure symptoms influences patients’ willingness to accept risks associated with mitral valve medical devices. These findings can inform shared decision-making discussions with patients who are being evaluated for transcatheter mitral valve repair.

Transcatheter Aortic Valve Replacement for Degenerated Transcatheter Aortic Valves: The TRANSIT International Project

2021 ◽  
Author(s):  
Luca Testa ◽  
Mauro Agnifili ◽  
Nicolas M. Van Mieghem ◽  
Didier Tchétché ◽  
Anita W. Asgar ◽  
...  
Keyword(s):  
New York ◽  
Transcatheter Aortic Valve Replacement ◽  
Heart Association ◽  
York Heart Association Class ◽  
Class Iii ◽  
Transcatheter Aortic Valve ◽  
Significant Difference ◽  
Association Class ◽  
New York Heart Association ◽  
Overall Mortality

Background: Transcatheter aortic valve replacement (TAVR) has determined a paradigm shift in the treatment of patients with severe aortic stenosis. However, the durability of bioprostheses is still a matter of concern, and little is known about the management of degenerated TAV. We sought to evaluate the outcomes of patients with a degenerated TAV treated by means of a second TAVR. Methods: The TRANSIT is an international registry that included cases of degenerated TAVR from 28 centers. Among around 40 000 patients treated with TAVR in the participating centers, 172 underwent a second TAVR: 57 (33%) for a mainly stenotic degenerated TAV, 97 (56%) for a mainly regurgitant TAV, and 18 (11%) for a combined degeneration. Overall, the rate of New York Heart Association class III/IV at presentation was 73.5%. Results: Valve Academic Research Consortium 2 device success rate was 79%, as a consequence of residual gradient (14%) or regurgitation (7%). At 1 month, the overall mortality rate was 2.9%, while rates of new hospitalization and New York Heart Association class III/IV were 3.6% and 7%, respectively, without significant difference across the groups. At 1 year, the overall mortality rate was 10%, while rates of new hospitalization and New York Heart Association class III/IV were 7.6% and 5.8%, respectively, without significant difference across the groups. No cases of valve thrombosis were recorded. Conclusions: Selected patients with a degenerated TAV may be safely and successfully treated by means of a second TAVR. This finding is of crucial importance for the adoption of the TAVR technology in a lower risk and younger population. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04500964.

Sign in / Sign up

Export Citation Format

Share Document